Cite
HARVARD Citation
Bajaj, H. et al. (2020). Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial. Diabetes, obesity & metabolism. 22 (7), pp. 1122-1131. [Online].